A new study from Massey University has revealed that the medicinal cannabis industry in New Zealand has undergone a dramatic transformation since the scheme was introduced in 2020. The research, led by public health expert Marta Rychert, raises concerns about the increasing prevalence of high-THC cannabis prescriptions, which may not be necessary for most patients’ clinical needs.
Rapid Growth and Shift to High-Potency Cannabis Products
The study found that the supply of medicinal cannabis in New Zealand has grown 14 times since 2020. Initially, most products prescribed were CBD-based and taken as oils or oral liquids. However, as of 2024, over 60% of approved products are THC-dominant, with many featuring high-potency dried cannabis flowers containing up to 25% THC.
This trend towards higher potency products has raised eyebrows. Rychert pointed out that such high levels of THC are uncommon in global medicinal cannabis practices. Most countries offer more balanced, lower-THC products to patients. She emphasized that there is little evidence supporting the need for these high concentrations, as lower THC products have been shown to be effective in clinical trials, particularly for pain management.
- The medicinal cannabis market has grown 14 times since 2020.
- Over 60% of prescriptions are now for high-potency THC products.
- There is limited clinical evidence supporting the need for such high THC levels.
Concerns Over Prescription Practices in Private Clinics
A key issue raised by the researchers was the role of private cannabis clinics in New Zealand’s medical cannabis industry. These clinics have improved access to treatments, but the study suggests that their commercial model may influence prescribing practices. Rychert and co-author Chris Wilkins expressed concern that some clinics might focus on selling high-THC products, regardless of the patient’s specific medical needs.
Rychert highlighted the potential conflict of interest in clinics that both prescribe and supply cannabis products. This dual role may encourage doctors to prescribe products that are more profitable, rather than those that are most appropriate for individual patients. She also raised concerns about clinics marketing their services through social media and other advertising platforms, which, while technically legal, may blur ethical lines.
Industry Scrutiny and Calls for Accountability
In response to the study, Dr. Afraz Adam, Chief Medical Officer at Cannaplus, a leading medicinal cannabis clinic, acknowledged that the concerns raised were valid. He supported increased scrutiny of the industry to ensure that patient safety and care remain the top priorities. Adam emphasized that Cannaplus follows strict procedures to ensure that cannabis is not a first-line treatment and only prescribes products that suit individual patient needs.
At Cannaplus, patients undergo a detailed screening process before receiving a prescription. The clinic maintains a policy of starting with the lowest THC concentration and increasing only if necessary. Dr. Adam also stressed the importance of communication between clinics and general practitioners to avoid potential issues like double-dipping or overprescribing.
Despite the growth of the medicinal cannabis industry, the study underscored the importance of careful regulation and scrutiny. With the market continuing to expand, the need for reliable, patient-centered practices is more crucial than ever.
Michael Brown is a seasoned journalist with a knack for uncovering compelling stories within the realm of cannabis. Through his investigative reporting and in-depth analysis, he sheds light on the regulatory challenges, market trends, and societal impacts of the burgeoning cannabis industry. Michael’s commitment to objective journalism and ethical reporting makes him a trusted voice in providing readers with balanced and informative articles about this rapidly evolving landscape.
